Document is current
Any future updates will be listed below
-
Authors
Hänel, Gerulf https://orcid.org/0000-0003-4685-6499
Angerer, Caroline
Petry, Katja
Lichtenegger, Felix S. https://orcid.org/0000-0003-3990-1802
Subklewe, Marion https://orcid.org/0000-0001-9154-9469
-
Funding
Funding for this research was provided by:
deutsche forschungsgemeinschaft (SFB1243, SU197/3-1)
miltenyi biotec
wilhelm sander-stiftung (2018.087.1)
Ludwig-Maximilians-Universität München
- License Information
-
More Information
Article History
Received: 29 June 2021
Accepted: 9 November 2021
First Online: 25 November 2021
Declarations
:
: G.H. declares no conflicts of interest. C.A. and K.P. are employed by Miltenyi Biotec. F.S.L. is employed by Hoffmann-La Roche. M.S. has received industry research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, and has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche. She sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, and serves on the speakers' bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was obtained by the Institutional Review Board of the LMU Munich.
: Informed consent was obtained from all individual participants included in the study.
